Historical Grant

RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)

NIH BRAIN Initiative cooperative agreement to accelerate translational development of recording and modulation devices for CNS disorders through milestone-driven UG3/UH3 funding and small clinical studies requiring FDA IDE pathways.

FindMyMoney.App
Published by FindMyMoney.App
Official source: National Institutes of Health (NIH)
💰 Funding Historical NOFO estimate: NIH anticipated $10M per year for 5 to 7 awards
📅 Deadline Historical reference
📍 Location United States
🏛️ Source National Institutes of Health (NIH)

RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)

Historical reference. The application cycle for NIH Notice of Funding Opportunity RFA-NS-25-021 is closed. The NIH notice listed September 28, 2026 as the final application due date and September 29, 2026 as the expiration date. No later receipt date appears in that notice, and no successor cycle is identified in the official NIH and Grants.gov records reviewed for this page. Do not treat the dates below as an open application window. This page preserves the scope and requirements of the closed notice for reference; check current NIH and Grants.gov listings before planning a future submission.

Archived opportunity summary

RFA-NS-25-021 was a National Institutes of Health BRAIN Initiative cooperative agreement for translational work on recording and/or stimulating devices for central nervous system disorders. Its purpose was to support regulatory preparation for a Significant Risk (SR) clinical study requiring an FDA Investigational Device Exemption (IDE), followed by a small clinical study. NIH described the clinical-trial status as optional at the opportunity level, but that wording did not mean an applicant could propose only nonclinical work: the notice required both UG3 and UH3 phases for every project.

The NOFO was issued by NIH with participation from the National Institute of Neurological Disorders and Stroke and other BRAIN Initiative institutes and centers. NIBIB participation was added by a related notice. The NIH page identifies RFA-NS-25-022 as a companion opportunity for projects proposing only the UH3 clinical phase. That companion notice is separate; its availability should be checked directly rather than inferred from this archived NOFO.

Archived termWhat the notice said
MechanismUG3/UH3 exploratory/developmental phased cooperative agreement
Last application due dateSeptember 28, 2026, by 5:00 p.m. local time of the applicant organization
NOFO expirationSeptember 29, 2026
Funds and anticipated awardsNIH anticipated $10 million per year for an estimated 5 to 7 awards
UG3 budgetNo more than $500,000 in direct costs per year
UH3 budgetShould rarely exceed $1,500,000 in direct costs per year
Maximum project lengthUG3 up to one year; UH3 up to four years; combined period no more than five years
Official noticeNIH RFA-NS-25-021

These were planning figures and limits in the notice, not a guaranteed award amount for an individual project. Budgets were expected to reflect the actual needs of each project. The anticipated annual program total and award count describe NIH’s forecast, not an entitlement or a promise that a fixed number of awards would be made in every cycle.

Program purpose and scientific scope

The notice targeted devices intended to record or stimulate activity in the human CNS to treat CNS disorders or improve understanding of the human brain. The translational emphasis was on moving a device toward an initial human study when key questions about device function, intended use, or final design could not practically be resolved through additional bench or animal work alone. An SR study, such as a study involving a chronic implant, had to require an FDA IDE. Non-Significant Risk (NSR) clinical studies were outside this NOFO’s supported clinical scope.

Each proposal had to focus on a single CNS condition within the mission of a participating institute or center. A competitive plan needed a credible bridge from device maturity and supporting evidence to regulatory review and clinical evaluation. The notice expected devices to be close to the final system and manufacturing process or to have relevant FDA Pre-Submission feedback. It also called for comprehensive supporting data appropriate to the intended patient population and indication, clinically meaningful outcome measures informed by stakeholders and literature, and a persuasive case for an IDE submission.

The project was designed as a two-stage progression. In UG3, the team would complete the nonclinical and regulatory activities necessary to obtain IDE and IRB approvals for the proposed SR study. NIH required a one-year UG3 phase. Only a project that obtained the necessary regulatory approvals and passed NIH administrative review could move to UH3. The UH3 phase supported the small clinical study and could last from one to four years, within the five-year combined limit. A clinical-only project was outside the scope of this notice; NIH directed those applicants to consider the companion UH3 notice instead.

The award mechanism was a cooperative agreement, which entails substantial federal scientific or programmatic involvement after award. NIH staff could help negotiate the final project plan, monitor progress, and participate in go/no-go decisions. Applicants needed to build measurable milestones into the work plan and understand that transition from UG3 to UH3 depended on required progress and approvals. The award was therefore not a conventional research grant with an automatic second phase.

Partnerships and device access

Participation in the BRAIN Initiative Public-Private Partnership Program was optional. Applicants could also work with a manufacturer outside that program or develop their own device. For projects relying on an industry partner, however, the application needed to document the partner’s interest in providing access to the device and data needed for the proposed work and IDE filing. The notice gave an executed collaborative research agreement or a partner letter as examples of documentation. Final negotiation did not have to be complete at application submission, but an executed agreement was required before an award could be issued.

The purpose of the partnership framework was to make appropriate device technology and existing safety or utility information available for early clinical research. A team should therefore have addressed device access, data rights, intellectual property, responsibilities, and timing as part of its feasibility plan. A reference to a prospective collaborator without evidence of access or engagement would not establish that the proposed study could proceed.

The notice encouraged real-time synchronization of device recordings with peripheral or ambulatory behavioral signals where relevant. Examples included phone or smartwatch signals. The proposed data collection could stream data rather than store it on the device, but the design should avoid requiring participants to carry cumbersome equipment that interferes with naturalistic behavior. Privacy and confidentiality protections also needed to be explained. These design considerations were part of the device’s research utility and participant burden, not merely technical details.

Eligibility preserved from the closed notice

Eligible applicant types included public and private higher education institutions; nonprofits with or without 501(c)(3) status; small businesses and other for-profit organizations; eligible local and federal government entities; U.S. territories or possessions; tribal governments and organizations; independent school districts; public housing authorities; faith-based or community-based organizations; and regional organizations. Businesses and institutions could apply directly when developing their own device or could collaborate with manufacturers.

Non-U.S. organizations were not eligible to apply. The notice also says that non-domestic components of U.S. organizations were not eligible, while foreign components as defined by NIH policy were allowed. Those phrases are not interchangeable: teams with international collaborators needed to distinguish an allowable foreign component from an ineligible non-domestic organizational component and consult NIH policy and program contacts for their specific arrangement.

The NOFO allowed new, resubmission, and revision application types. It did not list renewal applications. Eligibility of an organization did not by itself make a project responsive. The one-condition focus, device maturity, SR/IDE clinical pathway, two-phase structure, and fit with a participating institute’s mission remained central scope requirements.

Requirements for a historical application file

The following details describe the closed notice’s submission package; they are included for records and for teams comparing a future announcement with this cycle. They are not instructions to submit to an expired opportunity. Applicants were required to use the NIH Research (R) application instructions together with the opportunity-specific instructions. NIH warned that nonconforming or nonresponsive applications could be delayed, rejected, or withdrawn.

Applications had to be submitted electronically using NIH ASSIST, Grants.gov Workspace, or an institutional system-to-system route. Paper applications were not accepted. The applicant organization needed its System for Award Management registration and Unique Entity Identifier, Grants.gov registration, and required eRA Commons setup in place before submission. All PD(s)/PI(s) needed a valid eRA Commons ID in the Senior/Key Person Profile. The same UEI had to be used across the application and organizational registrations. Registration could take six weeks or more, so NIH advised organizations to begin early; incomplete registration was not a valid reason for missing a receipt date.

The application package contained several required attachments specific to the NOFO. It required a project Gantt chart of no more than one page, showing major tasks and estimated start and completion dates, and an Intellectual Property Strategy of no more than three pages. The notice also called for a Needs Assessment and a Long-term Patient Care Plan, each within its specified three-page limit. Required attachments needed the requested names and formats. The notice warned that omitting a required attachment or exceeding a stated limit could result in withdrawal, rather than merely a lower review score. Applicants also had to follow the application guide for the standard forms and other page limits.

The scientific narrative needed one coherent set of aims covering nonclinical testing and the clinical study. The Research Strategy had to explain the clinical need, the device and its capabilities, supporting evidence, intended population, meaningful outcomes, and how the proposed work would lead to adoption or further development. The UG3 plan needed an accelerated but credible sequence for regulatory work, including FDA interactions and IDE preparation where applicable, IRB approval planning, oversight arrangements, and objective milestones. The clinical protocol and trial details belonged in the applicable human-subjects and clinical-trials forms. A proposal that described only technical development without a plausible regulatory and clinical transition would not match the program’s stated purpose.

Applicants proposing work with a BRAIN PPP or other industry device partner needed to demonstrate partner interest and access to the device and relevant data. The IP strategy needed to identify rights or other barriers that could prevent the project from being performed or translated. Teams also needed a suitable plan for the long-term care of participants and for recruitment, retention, safety, and clinically meaningful outcome measurement. NIH’s review considered scientific importance and rigor, feasibility, investigators and environment, and the adequacy of human-subject protections, milestones, partnerships, and translation planning.

For electronic submission, the organization submitted through Grants.gov and tracked the application in eRA Commons. Errors identified by the submission systems had to be corrected by the due date and time. The authorized organizational representative was responsible for checking the assembled application in eRA Commons before the deadline. Those steps mattered because a successful transmission alone did not establish that the final application was complete, error-free, and accepted for review.

Reading this archive and checking for a future cycle

The requirements above belong to RFA-NS-25-021. They should not be assumed to govern a later funding notice. NIH may revise eligibility, receipt dates, attachment instructions, clinical scope, budget limits, and participating institutes when it issues a reissue. A team considering this research area should locate the active notice in official NIH or Grants.gov listings, confirm that it is open, and use that notice’s current application guide and forms. A prior application or this archived summary cannot substitute for those checks.

The source notice’s final due date was September 28, 2026, and its stated expiration date was September 29, 2026. Since both dates have passed and no next round is announced in the official records reviewed here, this entry is an archive rather than an invitation to apply. The archived award estimates and application steps remain useful for understanding the former program design, but prospective applicants need a newly published opportunity before preparing a submission.

Official references

Next step
Check official source